Literature DB >> 26209001

Triheptanoin Alleviates Ventricular Hypertrophy and Improves Myocardial Glucose Oxidation in Rats With Pressure Overload.

T Dung Nguyen1, Yasushige Shingu2, Paulo A Amorim1, Michael Schwarzer1, Torsten Doenst3.   

Abstract

OBJECTIVE: Cardiac hypertrophy is characterized by changes in substrate utilization and activity of the Krebs cycle. We assessed the effects of triheptanoin, an odd-chain fat that might support the Krebs cycle, on cardiac metabolism and function in a model of cardiac hypertrophy. METHODS AND
RESULTS: Rats were subjected to aortic banding (AoB) to induce pressure overload (PO). Starting at 1 week after AoB, rats were blindly fed a control diet or a special diet containing triheptanoin at 7% (T7 group) or 30% (T30 group) of total energy value. Six weeks after AoB, echocardiography revealed attenuated hypertrophy and improved diastolic function of the left ventricle. Isolated working heart perfusion showed similar cardiac power, fatty acid oxidation, substrate preference, and insulin response among groups. However, cardiac glucose oxidation (GO) was increased in the T30 group compared with the T7 and control groups. Blood levels of the odd-chain ketone body beta-hydroxypentanoate confirmed adequate bioavailability of triheptanoin. Importantly, they were directly proportional to cardiac GO.
CONCLUSIONS: Treatment with triheptanoin-enriched diet reduces ventricular hypertrophy and improves diastolic function in rats with PO, which is associated with enhanced cardiac GO. The results suggest targeting supplementation of the Krebs cycle to approach ventricular and metabolic remodeling in cardiac hypertrophy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Triheptanoin; anaplerosis; cardiac hypertrophy; cardiac metabolism

Mesh:

Substances:

Year:  2015        PMID: 26209001     DOI: 10.1016/j.cardfail.2015.07.009

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  5 in total

1.  Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.

Authors:  Sara Tucci; Ulrich Floegel; Frauke Beermann; Sidney Behringer; Ute Spiekerkoetter
Journal:  J Lipid Res       Date:  2016-11-24       Impact factor: 5.922

2.  Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.

Authors:  Melanie B Gillingham; Stephen B Heitner; Julie Martin; Sarah Rose; Amy Goldstein; Areeg Hassan El-Gharbawy; Stephanie Deward; Michael R Lasarev; Jim Pollaro; James P DeLany; Luke J Burchill; Bret Goodpaster; James Shoemaker; Dietrich Matern; Cary O Harding; Jerry Vockley
Journal:  J Inherit Metab Dis       Date:  2017-09-04       Impact factor: 4.982

3.  Reactivation of fatty acid oxidation by medium chain fatty acid prevents myocyte hypertrophy in H9c2 cell line.

Authors:  Saifudeen Ismael; R Renuka Nair
Journal:  Mol Cell Biochem       Date:  2020-09-30       Impact factor: 3.396

4.  Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience.

Authors:  Charles R Roe; Henri Brunengraber
Journal:  Mol Genet Metab       Date:  2015-10-24       Impact factor: 4.797

Review 5.  Protective Effect of Natural Medicinal Plants on Cardiomyocyte Injury in Heart Failure: Targeting the Dysregulation of Mitochondrial Homeostasis and Mitophagy.

Authors:  Qi Wang; Hao Su; Jinfeng Liu
Journal:  Oxid Med Cell Longev       Date:  2022-09-12       Impact factor: 7.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.